Pfizer

Paxlovid, an oral drug that treats COVID-19, is set to hit the commercial market next month after being managed by the United States federal government since its release. On Wednesday, Pfizer announced...

Paxlovid, an oral drug that treats COVID-19, will begin to enter the commercial market starting next month. At the same time, the US federal government is making sure that the country has enough supply,...

The Centers for Disease Control and Prevention on Tuesday recommended that everyone over 6 months old receive the updated COVID-19 shots approved by the Food and Drug Administration on Monday.

A study that put both COVID-19 shots to the test to see which was better for older adults found that the Moderna vaccine was superior.

The CDC is investigating bivalent booster shot safety after one of its monitoring systems flagged a potential risk of stroke among seniors.

New data from a trial in humans shows that the omicron-adapted COVID-19 booster made by Pfizer and BioNTech is safe and effective in older adults, according to the drugmakers.

The FDA expects to soon authorize omicron-targeting shots. The White House is planning to distribute them as part of a fall vaccination campaign, federal officials say.

The drug company says that its new mRNA vaccine produces an immune response against the BA.4 and BA.5 omicron subvariants.

The oral antiviral pill Paxlovid does not significantly reduce the risk of severe COVID-19 in patients at “standard risk” of poor outcomes, the drug’s maker reports.

A second booster — or fourth dose — will be necessary to improve the vaccine’s waning protection in the face of omicron, Pfizer’s CEO has stated. Whether the FDA will find the evidence compelling...